데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
387867-13-2COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1UXXQOJXBIDBUAC-UHFFFAOYSA-N387867-13-2DTXSID8048947CHEMBL124660CHEBI:90237White Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Tandutinib is a potent antagonist of platelet-derived growth factor receptor β (PDGFRβ), FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively). It less potently inhibits macrophage colony-stimulating factor 1 receptor (IC50 = 3.4 μM) and does not significantly inhibit other tyrosine or serine/threonine kinases. Tandutinib blocks the growth of cells expressing an internal tandem duplication within the juxtamembrane domain of the FLT3 receptor, found in some acute myelogenous leukemia cells. It also impairs the growth of colon cancer cells through its actions on the c-Kit receptor. Tandutinib reverses multidrug resistance in vitro by impairing the efflux activity of the multidrug resistance protein 7.
용도An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelody
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
정의ChEBI: An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a 6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl group, while the hydrogen attached to the nitrogen at position 4 s replaced by a (p-isopropoxyphenyl)aminocarbonyl group. Tandutinib is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT.